How would you approach a locally advanced ampullary carcinoma with BRCA1 mutation whose Whipple showed complete pathologic response after 5 cycles of neoadjuvant mFOLFIRINOX?
Patient refuses further mFOLFIRINOX but may be open to less aggressive regimens. Is there any role for PARP inhibitors?
Medical Oncologist
I assume this patient has pancreaticobiliary-type ampullary cancer. Unfortunately, no data to support adjuvant PARP agent. With BRACA positive status, one could complete the total of six months of treatment with gem/abraxane/cisplatin.
Sign in or Register to read more